Endometrial Changes Associated with Mifepristone: A Review.

IF 2 4区 医学 Q2 MEDICINE, GENERAL & INTERNAL
International Journal of General Medicine Pub Date : 2025-09-13 eCollection Date: 2025-01-01 DOI:10.2147/IJGM.S535797
Qianhui Lin, Yun Zhou
{"title":"Endometrial Changes Associated with Mifepristone: A Review.","authors":"Qianhui Lin, Yun Zhou","doi":"10.2147/IJGM.S535797","DOIUrl":null,"url":null,"abstract":"<p><p>Mifepristone is a well-established pharmaceutical agent in obstetrics and gynecology, which has expanded its therapeutic applications to Cushing's syndrome, meningioma, and even mental disease. The incidence of progesterone receptor modulator-associated endometrial changes (PAECs), characterized by cystic glandular dilatation and architectural complexity that mimic endometrial hyperplasia or carcinoma, is increasing. The precise molecular mechanisms remain incompletely understood. Hormonal influences may be central to PAECs pathogenesis. Histological heterogeneity has been observed between ectopic versus eutopic endometrium. The use of mifepristone at low doses (≤10 mg/d) in young women during the early follicular phase appears to be safe. Monitoring of estradiol(E<sub>2</sub>) levels before the management is recommended. Risk assessment and preventive strategies, such as intermittent treatment, transvaginal ultrasound and levonorgestrel intrauterine system (LNG-IUS), should be considered.</p>","PeriodicalId":14131,"journal":{"name":"International Journal of General Medicine","volume":"18 ","pages":"5503-5508"},"PeriodicalIF":2.0000,"publicationDate":"2025-09-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12442810/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of General Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2147/IJGM.S535797","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}
引用次数: 0

Abstract

Mifepristone is a well-established pharmaceutical agent in obstetrics and gynecology, which has expanded its therapeutic applications to Cushing's syndrome, meningioma, and even mental disease. The incidence of progesterone receptor modulator-associated endometrial changes (PAECs), characterized by cystic glandular dilatation and architectural complexity that mimic endometrial hyperplasia or carcinoma, is increasing. The precise molecular mechanisms remain incompletely understood. Hormonal influences may be central to PAECs pathogenesis. Histological heterogeneity has been observed between ectopic versus eutopic endometrium. The use of mifepristone at low doses (≤10 mg/d) in young women during the early follicular phase appears to be safe. Monitoring of estradiol(E2) levels before the management is recommended. Risk assessment and preventive strategies, such as intermittent treatment, transvaginal ultrasound and levonorgestrel intrauterine system (LNG-IUS), should be considered.

与米非司酮相关的子宫内膜改变:综述。
米非司酮是一种成熟的妇产科药物,其治疗应用已扩展到库欣综合征、脑膜瘤,甚至精神疾病。孕激素受体调节剂相关性子宫内膜改变(PAECs)的发生率正在增加,其特征是囊性腺体扩张和结构复杂,类似于子宫内膜增生或癌。精确的分子机制仍未完全了解。激素的影响可能是paec发病机制的核心。在异位和异位子宫内膜之间观察到组织学异质性。年轻女性在卵泡早期使用低剂量(≤10mg /d)米非司酮似乎是安全的。建议在治疗前监测雌二醇(E2)水平。应考虑风险评估和预防策略,如间歇性治疗、经阴道超声和左炔诺孕酮宫内系统(LNG-IUS)。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
International Journal of General Medicine
International Journal of General Medicine Medicine-General Medicine
自引率
0.00%
发文量
1113
审稿时长
16 weeks
期刊介绍: The International Journal of General Medicine is an international, peer-reviewed, open access journal that focuses on general and internal medicine, pathogenesis, epidemiology, diagnosis, monitoring and treatment protocols. The journal is characterized by the rapid reporting of reviews, original research and clinical studies across all disease areas. A key focus of the journal is the elucidation of disease processes and management protocols resulting in improved outcomes for the patient. Patient perspectives such as satisfaction, quality of life, health literacy and communication and their role in developing new healthcare programs and optimizing clinical outcomes are major areas of interest for the journal. As of 1st April 2019, the International Journal of General Medicine will no longer consider meta-analyses for publication.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信